<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5187">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776941</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0538</org_study_id>
    <secondary_id>NCI-2021-00218</secondary_id>
    <secondary_id>2020-0538</secondary_id>
    <nct_id>NCT04776941</nct_id>
  </id_info>
  <brief_title>Expressive Writing for the Management of Stress in Cancer Survivors</brief_title>
  <official_title>COVID-19: A Virtual Feasibility Study to Manage Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates the effect of expressive writing for the management of stress&#xD;
      in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in&#xD;
      cancer survivors related to concerns about family, career, relationships, finances, side&#xD;
      effects of treatment, and death. This stress can be further exacerbated by social upheavals&#xD;
      such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted&#xD;
      access to in-person health care and reduced social interaction with family and friends.&#xD;
      Together with the economic uncertainties that come with this pandemic, these factors are&#xD;
      likely to increase cancer survivors' stress levels. Expressive writing may provide a medium&#xD;
      through which cancer survivors confront stressors and find meaning in their experience. The&#xD;
      goal of this trial is to learn more about the experiences of cancer survivors during&#xD;
      stressful times.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the feasibility of the virtual study for cancer survivors. II. To&#xD;
      preliminarily assess the impact of the intervention for cancer survivors.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I (INTERVENTION): Patients complete questionnaires over 30 minutes about their mood,&#xD;
      health, and income at baseline, and 1, 3, and 6 months. Patients also read brief positive&#xD;
      messages and write essays about their experiences over 30 minutes (non-stop) once weekly (QW)&#xD;
      for 3 weeks.&#xD;
&#xD;
      ARM II (CONTROL): Patients complete questionnaires over 30 minutes about their mood, health,&#xD;
      and income at baseline, and 1, 3, and 6 months. Patients also read brief neutral messages and&#xD;
      write essays about neutral topics over 30 minutes (non-stop) QW for 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant response rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study completion rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention adherence rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in stress</measure>
    <time_frame>Baseline and 1-, 3-, and 6-month follow-up</time_frame>
    <description>Perceived stress will be measured with the 4-item Perceived Stress Scale. Scale scores range from 0-16, with low scores indicating low perceived stress and high scores indicating high perceived stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline and 1-, 3-, and 6-month follow-up</time_frame>
    <description>Quality of life will be measured with the 7-item Functional Assessment of Cancer Therapy (FACT-G7). The items are rated on a 5-point scale from 0 - &quot;not at all&quot;, to 4 - &quot;very much&quot;. Scores range from 0-28, with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical health (sleep, fatigue, and cancer related morbidities)</measure>
    <time_frame>Baseline and 1-, 3-, and 6-month follow-up</time_frame>
    <description>Sleep will be measured with the 19-item Pittsburgh Sleep Quality Index (PSQI). The PSQI global score ranges from 0 to 21, with a cut-off score of 5 or greater indicating poor sleep quality.&#xD;
Fatigue will be measured with the 4-item PROMIS Fatigue Short Form. This measure assesses the magnitude of fatigue in the past 7 days. Items are measured on a five-point scale (1= &quot;not at all&quot;; 5 = &quot;very much&quot;) and summed. Higher scores indicate greater fatigue.&#xD;
Cancer related morbidities will be self-reported by participants and verified through medical record review.&#xD;
.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychological health (depressive symptoms, anxiety, and fear of cancer recurrence)</measure>
    <time_frame>Baseline and 1-, 3-, and 6-month follow-up</time_frame>
    <description>Depressive symptoms will be measured with the 4-item PROMIS Depression Short Form. This measure assesses the frequency of depressive symptoms in the past 7 days. Items are measured on a five-point scale (1= &quot;never&quot;; 5 = &quot;always&quot;) and summed. Higher scores indicate more depressive symptoms.&#xD;
Anxiety will be measured with the 4-item PROMIS Anxiety Short Form. This measure assesses the frequency of anxiety in the past 7 days. Items are measured on a five-point scale (1= &quot;never&quot;; 5 = &quot;always&quot;) and summed. Higher scores indicate greater anxiety.&#xD;
Fear of cancer recurrence will be measured with a single item added to the quality of life measure (F</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (questionnaires, messages, writing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief positive messages and write essays about their experiences over 30 minutes (non-stop) QW for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (questionnaires, messages, writing)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief neutral messages and write essays about neutral topics over 30 minutes (non-stop) QW for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Read positive messages</description>
    <arm_group_label>Arm I (questionnaires, messages, writing)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Write about positive experiences</description>
    <arm_group_label>Arm I (questionnaires, messages, writing)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Write about neutral topics</description>
    <arm_group_label>Arm II (questionnaires, messages, writing)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Read neutral messages</description>
    <arm_group_label>Arm II (questionnaires, messages, writing)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (questionnaires, messages, writing)</arm_group_label>
    <arm_group_label>Arm II (questionnaires, messages, writing)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Arm I (questionnaires, messages, writing)</arm_group_label>
    <arm_group_label>Arm II (questionnaires, messages, writing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Have a diagnosis of cancer within the past 3 years&#xD;
&#xD;
          -  Are able to speak and read in English&#xD;
&#xD;
          -  Have access to a computer or smart phone with internet connection&#xD;
&#xD;
          -  All disease sites and all cancer stages are eligible for enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Non-English speakers will be excluded because this is a feasibility study that will&#xD;
             enroll only a limited number of participants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qian Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Lu</last_name>
      <phone>713-745-8324</phone>
      <email>qlu@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Qian Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

